Corcept Therapeutics, Inc. (CORT)

Oncology Corporate Profile

Stock Performance

19.1300
0.9300

3 Month Stock History Chart

HQ Location

149 Commonwealth Drive
Menlo Park, CA 94025

Company Description

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company's first FDA-approved medication.

Website: http://www.corcept.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
mifepristoneprogesterone receptor antagonistBreast cancerI
mifepristone (+ eribulin)progesterone receptor antagonistBreast cancerI

View additional information on product candidates here »

Source: http://www.corcept.com

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/16/2017 12:18 pm

8/16/2017 12:18 pm

8/16/2017 12:18 pm

8/16/2017 12:18 pm

8/16/2017 12:18 pm

8/14/2017 06:18 am

8/12/2017 06:18 pm

8/9/2017 12:18 am

8/9/2017 12:18 am

8/9/2017 12:18 am

8/7/2017 06:18 am

8/3/2017 12:18 pm

8/2/2017 06:23 pm

8/2/2017 12:18 pm

8/2/2017 06:26 am